In any case, as a result of the expansion of public spending globally and nationally, a level of inflation that had not been seen in the last 40 years has been unleashed inadvertently. The same has not occurred, however, with the national productive sector, as evidenced by the cases of agriculture and local manufacturing, which have had, in relative terms, low performance in their contributions to the gross domestic product.
Strata oncology free#
For example, this is the case with remittances, tourism, and free trade zones.
This global economic reactivation has allowed the components of the external sector of the Dominican economy to perform remarkably well. To get out of the recession caused by the pandemic, central banks around the world issued large amounts of money, which allowed the expansion of public spending and, therefore, the reactivation of economic growth. It was understood that it was essential to guide all sectors of the country in the strategic vision of moving in the same direction to overcome the most severe global crisis in a century.
In the political sphere, there was a kind of truce or a prolongation of the honeymoon. The vaccine to combat Covid-19 had not yet been discovered, and the economy had collapsed due to global confinement.įaced with such a dramatic situation, an atmosphere of national unity prevailed to cope with the severity of the health, economic and social crisis. However, the national situation, like the world situation, was a crisis. Nevertheless, it had high hopes for the promised change. The platform, which integrates comprehensive genomic profiling and highly quantitative RNA expression profiling, enables comprehensive molecular insights from a single, minute tumor tissue specimen.As a new government emerged in August 2020, Dominican society was under the spell of illusion. Led by Dan Rhodes, Ph.D., co-founder and Chief Executive Officer, Strata Oncology is a precision oncology company involved in expanding its comprehensive genomic and transcriptomic profiling platform to deliver a portfolio of treatment selection tests for solid tumors. The proceeds will be used to accelerate the development of Strata Oncology’s personalized minimal residual disease (MRD) assay for early-stage cancers and advance its pipeline of novel RNA-based treatment selection tests for solid tumors. Strata Oncology’s existing investors, including Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital and Renaissance Venture Capital Fund also participated in the financing, which brings the company’s total raised to date to over $130m since inception. Wellington Management led the financing and was joined by other new investors including Cormorant Asset Management, Monashee Investment Management and Highside Capital Management.
Strata oncology series#
Strata Oncology, Inc., an Ann Arbor, Mich.-based precision oncology company advancing molecular indications for cancer therapies, raised $90m in Series C financing.
0 kommentar(er)
